Regorafenib in metastatic colorectal cancer.

Regorafenib in metastatic colorectal cancer.

Item
http://www.wikidata.org/entity/Q27852864
CIViC databaseA Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors.Small molecule adenosine 5'-monophosphate activated protein kinase (AMPK) modulators and human diseasesResistance to multikinase inhibitor actions mediated by insulin like growth factor-1Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy.Dependence receptors and colorectal cancer.Real-life treatment of metastatic colorectal cancer with regorafenib: a single-centre review.A phase I study to investigate the metabolism, excretion, and pharmacokinetics of [14C]fruquintinib, a novel oral selective VEGFR inhibitor, in healthy Chinese male volunteers.
P2860

Regorafenib in metastatic colorectal cancer.

Item
http://www.wikidata.org/entity/Q27852864
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Regorafenib in metastatic colorectal cancer.
@ast
Regorafenib in metastatic colorectal cancer.
@en
Regorafenib in metastatic colorectal cancer.
@nl
type
label
Regorafenib in metastatic colorectal cancer.
@ast
Regorafenib in metastatic colorectal cancer.
@en
Regorafenib in metastatic colorectal cancer.
@nl
prefLabel
Regorafenib in metastatic colorectal cancer.
@ast
Regorafenib in metastatic colorectal cancer.
@en
Regorafenib in metastatic colorectal cancer.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Regorafenib in metastatic colorectal cancer
@en
P2093
P2860
P304
P31
P356
10.1586/14737140.2014.894887
P433
P478
P50
P577
P698
P921